The North America Newborn Screening Market is projected for steady growth over the coming decade owing to technological advancements and increased public health initiatives. Valued at USD 1,320 Million in 2025, the market is expected to reach USD 2,630 Million by 2035 at a CAGR of 7.0% from 2024 to 2035. Key industry players driving innovation include PerkinElmer Inc. and Bio-Rad Laboratories, Inc., who continue to set new standards in newborn health screening services across the region.
The economic impact of tariffs on "North America Newborn Screening Market".
Market Growth Drivers
Government Initiatives and Mandatory Screening Programs: Several US states and Canadian provinces have recently expanded their mandatory panel of newborn screenings to cover more diseases, resulting in higher test volumes. For instance, in March 2024, the US Department of Health and Human Services updated the Recommended Uniform Screening Panel (RUSP) to include additional rare disorders, compelling regional healthcare systems—like those utilizing PerkinElmer’s solutions—to upgrade and broaden their test offerings.
Technological Advancements in Screening Methods: The growing adoption of next-generation sequencing and tandem mass spectrometry has significantly improved the accuracy and range of detectable conditions. Companies like Bio-Rad Laboratories, Inc. have introduced high-throughput platforms and automation, reducing costs and turnaround times. Such innovation directly supports more comprehensive screening in major North American health systems.
Market Trends
Expansion of Screening Panels: Health authorities in North America are increasingly advocating for inclusive and comprehensive newborn screening, leading providers, such as PerkinElmer Inc., to expand their test portfolio. In early 2024, advancements in genetic analysis enabled the inclusion of additional metabolic and genetic conditions, furthering the market’s scope and attracting public and private investment in comprehensive newborn care solutions.
Adoption of Digital Health Technologies: The integration of digital technologies like data management platforms, telehealth, and electronic health records (EHRs) is a growing trend in newborn screening. For example, Natus Medical Incorporated unveiled an EHR-integrated newborn screening platform in February 2024, enhancing communication between laboratories, clinicians, and parents, ultimately improving patient outcomes and workflow efficiency.
Market Opportunities
Emergence of Point-of-Care (POC) Screening Devices: The commercialization of POC devices by companies like Thermo Fisher Scientific presents opportunities for rapid, on-site diagnosis, particularly in rural and underserved communities across North America. These portable solutions promise to further increase early detection rates and reduce the time to intervention.
Expansion into Genetic Disorder Screening: Companies such as Bio-Rad Laboratories, Inc. are exploring new market niches by developing targeted kits for genetic and rare disorders. As genetic testing reimbursement improves, significant opportunities will result for robust market expansion.
North America Newborn Screening Market Revenue (USD Million), 2020-2035
The chart illustrates a steady increase in market revenue from 2020 to 2035. Starting at USD 920 Million in 2020, growth accelerates through the forecast period due to increased adoption of advanced screening technologies and comprehensive public health strategies. A significant uptick is observed post-2024, reflecting recent regulatory changes and growing awareness. By 2035, the market is forecasted to reach USD 2,630 Million, underscoring the region's commitment to improving neonatal health outcomes.
North America Newborn Screening Market by Regions Share (%), 2025
The pie chart showcases the market share distribution across North America in 2025. The United States dominates the market with a 70% share, attributed to advanced healthcare infrastructure and widespread adoption of newborn screening programs. Canada follows with 18%, owing to national initiatives and public health funding, while Mexico accounts for 7%. Remaining regions (Caribbean and Others) together represent 5%. The data underscores market concentration in developed economies while highlighting potential for growth in emerging North American markets.
Recent Developments in North America Newborn Screening Market
In May 2024, PerkinElmer Inc. announced the launch of its NeoLABS Digital Platform tailored for newborn screening programs in the US and Canada. This digital workflow solution seamlessly integrates with laboratory equipment and the electronic health record ecosystem to streamline sample tracking, billing, and parental communication, marking a milestone for the digital transformation of newborn screening workflows.
In April 2024, Bio-Rad Laboratories, Inc. introduced a next-generation tandem mass spectrometry kit capable of screening additional metabolic and genetic disorders with higher sensitivity and specificity. The kit was rapidly adopted by several major North American public health laboratories, driving state-level expansions of mandatory newborn testing panels.
In March 2024, Natus Medical Incorporated formed a strategic partnership with the Canadian Neonatal Foundation to pilot an EHR-integrated newborn screening information system in multiple Canadian provinces. This project is aimed at reducing diagnostic delays, enhancing patient data accessibility, and setting a new national standard for newborn care digitalization.
Press Releases